ElevateBio removes barriers, accelerating the development of visionary therapies.

Committed to identifying and nurturing
innovation in cell and gene therapy

Our portfolio companies benefit from our entrepreneurial and flexible culture. We accelerate early-stage companies through capital and expertise, allowing them to focus on science, research, and development.
Viralym-M (ALVR105)
Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of Virus-Associated Hemorrhagic-Cystitis
Treatment of CMV
Treatment of ADV
Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV
Treatment of BKV
Treatment of CMV
ALVR106
Multi-VSTs targeting Respiratory syncytial virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of RSV, Influenza, PIV, & hMPV
Treatment of RSV, Influenza, PIV, & hMPV
ALVR109
Single-VST targeting SARS-CoV-2
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of COVID-19
ALVR107
Single-VST targeting Hepatitis B (HBV)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HBV
ALVR108
Single-VST targeting Human Herpesvirus-8 (HHV-8)
Target Indication
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HHV-8
HA-1 TCR
T cell receptor (TCR) T cell therapy targeting HA-1 expressing tumors designed to manage post-hematopoietic stem cell transplant leukemic relapse
Indication
Preclinical
Phase 1
Phase 2
Phase 3
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

We’re the partner of choice for the world’s most innovative academic researchers and entrepreneurs.

Building an alliance with Massachusetts General Hospital

The strategic partnership gives MGH preferred access to ElevateBio’s BaseCamp research, process development, and manufacturing facility. ElevateBio will support a variety of MGH’s cell and gene therapy research programs. Our organizations will work together to identify cell and gene technologies and create therapeutics companies.

learn more

Academic researchers provide the vision, we provide the acceleration.

We’re pioneering new methods to develop next generation, cell, viral, and regenerative therapies. We offer expertise to our portfolio companies and partners to accelerate the development of cell and gene therapies, from cGMP manufacturing suites to protein engineering, virology, and immunology labs.

explore basecamp

Work with a team that delivers decades of experience

Meet the scientists and operators that bring decades of shared knowledge to the development of life-transforming cell and gene therapies. Their know-how moves potential product candidates from concept to commercialization.

meet the team